Read by QxMD icon Read


S Shams, D Fällmar, S Schwarz, L-O Wahlund, D van Westen, O Hansson, E-M Larsson, S Haller
BACKGROUND AND PURPOSE: There are, to date, no MR imaging diagnostic markers for Lewy body dementia. Nigrosome 1, containing dopaminergic cells, in the substantia nigra pars compacta is hyperintense on SWI and has been called the swallow tail sign, disappearing with Parkinson disease. We aimed to study the swallow tail sign and its clinical applicability in Lewy body dementia and hypothesized that the sign would be likewise applicable in Lewy body dementia. MATERIALS AND METHODS: This was a retrospective cross-sectional multicenter study including 97 patients (mean age, 65 ± 10 years; 46% women), consisting of the following: controls (n = 21) and those with Lewy body dementia (n = 19), Alzheimer disease (n = 20), frontotemporal lobe dementia (n = 20), and mild cognitive impairment (n = 17)...
July 13, 2017: AJNR. American Journal of Neuroradiology
Koji Kamagata, Tomoya Nakatsuka, Ryuji Sakakibara, Yohei Tsuyusaki, Tomohiro Takamura, Kanako Sato, Michimasa Suzuki, Masaaki Hori, Kanako K Kumamaru, Tsutomu Inaoka, Shigeki Aoki, Hitoshi Terada
No abstract text is available yet for this article.
March 22, 2017: Neuroradiology
Koji Kamagata, Tomoya Nakatsuka, Ryuji Sakakibara, Yohei Tsuyusaki, Tomohiro Takamura, Kanako Sato, Michimasa Suzuki, Masaaki Hori, Kanako K Kumamaru, Tsutomu Inaoka, Shigeki Aoki, Hitoshi Terada
INTRODUCTION: The characteristics of dementia with Lewy bodies (DLB), Alzheimer's disease (AD) and amnestic mild cognitive impairment (a-MCI) overlap but require different treatments; therefore, it is important to differentiate these pathologies. Assessment of dopamine uptake in the striatum using dopamine transporter (DaT) single-photon emission computed tomography (SPECT) is the gold standard for diagnosing DLB; however, this modality is expensive, time consuming and involves radiation exposure...
January 2017: Neuroradiology
L A Massey, M A Miranda, O Al-Helli, H G Parkes, J S Thornton, P-W So, M J White, L Mancini, C Strand, J Holton, A J Lees, T Revesz, T A Yousry
BACKGROUND: The anatomy of the substantia nigra on conventional MRI is controversial. Even using histological techniques it is difficult to delineate with certainty from surrounding structures. We sought to define the anatomy of the SN using high field spin-echo MRI of pathological material in which we could study the anatomy in detail to corroborate our MRI findings in controls and Parkinson's disease and progressive supranuclear palsy. METHODS: 23 brains were selected from the Queen Square Brain Bank (10 controls, 8 progressive supranuclear palsy, 5 Parkinson's disease) and imaged using high field 9...
2017: NeuroImage: Clinical
Yoonho Nam, Sung-Min Gho, Dong-Hyun Kim, Eung Yeop Kim, Jongho Lee
PURPOSE: To enhance the visibility of nigrosome 1 in substantia nigra, which has recently been suggested as an imaging biomarker for Parkinson's disease (PD) at 3T magnetic resonance imaging (MRI). MATERIALS AND METHODS: The substantia nigra structure was visualized at 3T MRI using multiecho susceptibility map-weighted imaging (SMWI) in 15 healthy volunteers and 6 patients with Parkinson's disease (PD). The visibility of nigrosome 1 was further enhanced by acquiring data in an oblique-coronal imaging plane at a high spatial resolution (0...
November 11, 2016: Journal of Magnetic Resonance Imaging: JMRI
Katherine A Fu, Romil Nathan, Ivo D Dinov, Junning Li, Arthur W Toga
BACKGROUND: The nigrosome-1 region of the substantia nigra (SN) undergoes the greatest and earliest dopaminergic neuron loss in Parkinson's disease (PD). As T2-weighted magnetic resonance imaging (MRI) scans are often collected with routine clinical MRI protocols, this investigation aims to determine whether T2-imaging changes in the nigrosome-1 are related to clinical measures of PD and to assess their potential as a more clinically accessible biomarker for PD. METHODS: Voxel intensity ratios were calculated for T2-weighted MRI scans from 47 subjects from the Parkinson's Progression Markers Initiative database...
2016: Frontiers in Neurology
Frederick J A Meijer, Stefan C Steens, Anouke van Rumund, Anne-Marie van Cappellen van Walsum, Benno Küsters, Rianne A J Esselink, Marcel M Verbeek, Bastiaan R Bloem, Bożena Goraj
BACKGROUND: Previous case-control studies have suggested that the absence of a swallow-tail appearance in the substantia nigra on high-resolution SWI, representing nigrosome-1, has high accuracy to identify Parkinson's disease (PD). The first goal of our study was to evaluate nigrosome-1 ex vivo using optimized high-resolution susceptibility sensitive MRI. Our second goal was to evaluate its diagnostic value in vivo using a clinical 3T SWI sequence to differentiate between PD and atypical parkinsonism (AP) in a cohort of patients with early-stage parkinsonism...
2016: Polish Journal of Radiology
Se Won Oh, Na-Young Shin, Jae Jung Lee, Seung-Koo Lee, Phil Hyu Lee, Soo Mee Lim, Jin Woo Kim
OBJECTIVE: The purpose of this study is to evaluate direct in vivo visualization of nigrosome-1 in substantia nigra (SN) with 3D FLAIR imaging and its diagnostic value in predicting the intactness of presynaptic dopaminergic function of the nigrostriatal pathway. MATERIALS AND METHODS: Forty-five patients showing parkinsonism who underwent both 3D FLAIR and dopamine transporter (DAT) imaging were recruited. In total, 90 SNs were reviewed on axial 3D FLAIR images...
November 2016: AJR. American Journal of Roentgenology
Jong-Min Kim, Hye-Jin Jeong, Yun Jung Bae, Sung-Yeon Park, Eunhee Kim, Seo Young Kang, Eung Seok Oh, Kyeong Joon Kim, Beomseok Jeon, Sang Eun Kim, Zang-Hee Cho, Young-Bo Kim
BACKGROUND: Seven Tesla (7T) MRI can visualize anatomical alterations occurring in a hyperintense structure of the substantia nigra in Parkinson's disease (PD). OBJECTIVE: We investigated whether 7T MRI can detect the loss of substantia nigra hyperintensity in patients with PD, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). METHODS: Using 7T MRI, we evaluated 26 healthy subjects, 30 patients with PD, 7 patients with MSA, and 3 patients with PSP...
May 2016: Parkinsonism & related Disorders
P Gao, P-Y Zhou, G Li, G-B Zhang, P-Q Wang, J-Z Liu, F Xu, F Yang, X-X Wu
OBJECTIVE: To assess the imaging features of nigrosomes-1 in the substantia nigra through 3T MR susceptibility weighted imaging (SWI) and its disease-specific changes for the diagnosis of Parkinson's disease (PD). PATIENTS AND METHODS: A total of 116 subjects were included in this study and allocated into 3 groups: 54 patients diagnosed with PD were assigned to the PD group, 51 age- and sex-matched volunteers without PD served as the control N-PD group, and 11 clinically suspected PD patients were allocated to the undiagnosed (UD) group...
December 2015: European Review for Medical and Pharmacological Sciences
Young Hee Sung, Young Noh, Jongho Lee, Eung Yeop Kim
Purpose To explore the utility of nigrosome 1 with 3-T magnetic resonance (MR) imaging to differentiate idiopathic Parkinson disease (IPD) from drug-induced parkinsonism (DIP). Materials and Methods The institutional review board approved this study, and participants gave informed consent. This study enrolled patients with DIP (n = 20) and IPD (n = 29) who underwent N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane ((18)F-FP-CIT) positron emission tomography (PET) and healthy participants (n = 20)...
June 2016: Radiology
Y Noh, Y H Sung, J Lee, E Y Kim
BACKGROUND AND PURPOSE: In the early stages of idiopathic Parkinson disease, motor symptoms are usually asymmetric. We aimed to assess the feasibility of nigrosome 1 detection at 3T MR imaging to analyze the agreement of its asymmetry and clinical laterality. MATERIALS AND METHODS: High-resolution 3D multiecho imaging was performed at 3T MR imaging in 13 healthy subjects and 24 patients with idiopathic Parkinson disease confirmed by N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl) nortropane ((18)F-FP-CIT) PET...
November 2015: AJNR. American Journal of Neuroradiology
W Michael Zawada, Robert E Mrak, JoAnn Biedermann, Quinton D Palmer, Stephen M Gentleman, Orwa Aboud, W Sue T Griffin
BACKGROUND: In rodent models of Parkinson's disease (PD), dopamine neuron loss is accompanied by increased expression of angiotensin II (AngII), its type 1 receptor (AT1), and NADPH oxidase (Nox) in the nigral dopamine neurons and microglia. AT1 blockers (ARBs) stymie such oxidative damage and neuron loss. Whether changes in the AngII/AT1/Nox4 axis contribute to Parkinson neuropathogenesis is unknown. Here, we studied the distribution of AT1 and Nox4 in dopamine neurons in two nigral subregions: the less affected calbindin-rich matrix and the first-affected calbindin-poor nigrosome 1 of three patients, who were clinically asymptomatic, but had nigral dopamine cell loss and Braak stages consistent with a neuropathological diagnosis of PD (prePD)...
February 3, 2015: Acta Neuropathologica Communications
Stéphane Lehéricy, Eric Bardinet, Cyril Poupon, Marie Vidailhet, Chantal François
A hallmark of Parkinson's disease (PD) is the progressive neurodegeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc). Dopaminergic denervation is commonly imaged using radiotracer imaging in target structures such as the striatum. Until recently, imaging made only a modest contribution to detecting neurodegenerative changes in the substantia nigra (SN) directly. Histologically, the SN is subdivided into the ventral pars reticulata and the dorsal pars compacta, which is composed of dopaminergic neurons...
November 2014: Movement Disorders: Official Journal of the Movement Disorder Society
Christoph Mueller, Bernadette Pinter, Eva Reiter, Michael Schocke, Christoph Scherfler, Werner Poewe, Klaus Seppi, Anna I Blazejewska, Stefan T Schwarz, Nin Bajaj, Dorothee P Auer, Penny A Gowland
No abstract text is available yet for this article.
May 13, 2014: Neurology
Stefan T Schwarz, Mohammed Afzal, Paul S Morgan, Nin Bajaj, Penny A Gowland, Dorothee P Auer
There is no well-established in vivo marker of nigral degeneration in Parkinson's disease (PD). An ideal imaging marker would directly mirror the loss of substantia nigra dopaminergic neurones, which is most prominent in sub-regions called nigrosomes. High-resolution, iron-sensitive, magnetic resonance imaging (MRI) at 7T allows direct nigrosome-1 visualisation in healthy people but not in PD. Here, we investigated the feasibility of nigrosome-1 detection using 3T - susceptibility-weighted (SWI) MRI and the diagnostic accuracy that can be achieved for diagnosing PD in a clinical population...
2014: PloS One
Anna I Blazejewska, Stefan T Schwarz, Alain Pitiot, Mary C Stephenson, James Lowe, Nin Bajaj, Richard W Bowtell, Dorothee P Auer, Penny A Gowland
OBJECTIVE: This study assessed whether high-resolution 7 T MRI allowed direct in vivo visualization of nigrosomes, substructures of the substantia nigra pars compacta (SNpc) undergoing the greatest and earliest dopaminergic cell loss in Parkinson disease (PD), and whether any disease-specific changes could be detected in patients with PD. METHODS: Postmortem (PM) midbrains, 2 from healthy controls (HCs) and 1 from a patient with PD, were scanned with high-resolution T2*-weighted MRI scans, sectioned, and stained for iron and neuromelanin (Perl), TH, and calbindin...
August 6, 2013: Neurology
Lixia Lu, Frauke Neff, Daniel Alvarez Fischer, Carmen Henze, Etienne C Hirsch, Wolfgang H Oertel, Jürgen Schlegel, Andreas Hartmann
Parkinson's disease (PD) is characterized by loss of dopaminergic (DA) neurons in the human midbrain, which varies greatly among mesencephalic subregions. The genetic expression profiles of mesencephalic DA neurons particularly prone to degenerate during PD (nigrosome 1 within the substantia nigra pars compacta-SNpc) and those particularly resistant in the disease course (central grey substance-CGS) were compared in five control subjects by immuno-laser capture microdissection followed by RNA arbitrarily primed PCR...
August 2006: Neurobiology of Disease
Mahmoud M Iravani, Emilie Syed, Michael J Jackson, Louisa C Johnston, Lance A Smith, Peter Jenner
Standard MPTP treatment regimens in primates result in > 85% destruction of nigral dopaminergic neurons and the onset of marked motor deficits that respond to known symptomatic treatments for Parkinson's disease (PD). The extent of nigral degeneration reflects the late stages of PD rather than events occurring at its onset. We report on a modified MPTP treatment regimen that causes nigral dopaminergic degeneration in common marmosets equivalent to that occurring at the time of initiation of motor symptoms in man...
February 2005: European Journal of Neuroscience
Chang-Lin Liang, Omar Nelson, Umar Yazdani, Parichehr Pasbakhsh, Dwight C German
The dopaminergic neurons in the ventral substantia nigra (SN) are significantly more vulnerable to degeneration in Parkinson's disease (PD) than the dopaminergic neurons in the ventral tegmental area (VTA). The ventral SN neurons also contain significantly more neuromelanin pigment than the dopaminergic neurons in the VTA. In vitro data indicate that neuromelanin pigment is formed from the excess cytosolic catecholamine that is not accumulated into synaptic vesicles by the vesicular monoamine transporter-2 (VMAT2)...
May 17, 2004: Journal of Comparative Neurology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"